Blog

UKI2S biotech company CellCentric, University of Cambridge spinout, has raised $26m to fund clinical testing of its first-in-class oncology drug candidate, CCS1477. CellCentric focuses on treating prostate cancer, as well as multiple other cancers. Their new drug candidate addresses the large and increasing population of patients – upwards of 80,000 people each year — who […]

read more

We work closely with our partner laboratories to identify commercial opportunities arising from their world-class research and we are excited to announce investments in three promising university spinouts and follow-on funding for a leading life science firm. The UCL Technology Fund and UKI2S, alongside support from Innovate UK, have invested in UCL spinout company Glialign […]

read more

1 2 3 21